Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

OBJECTIVE: The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (ClinicalTrials.gov reg. no. NCT01179048) demonstrated a reduced risk of cardiovascular (CV) events for patients with type 2 diabetes who received the glucagon-like peptide 1 recepto...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Care
Main Authors: Buse, John B., Bain, Stephen C., Mann, Johannes F.E., Nauck, Michael A., Nissen, Steven E., Pocock, Stuart, Poulter, Neil R., Pratley, Richard E., Linder, Martin, Monk Fries, Tea, Ørsted, David D., Zinman, Bernard
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2020
Assuntos:
Cardiovascular and Metabolic Risk
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7305014/
https://ncbi.nlm.nih.gov/pubmed/32366578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc19-2251
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados